Roger L Albin Selected Research

Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)

5/2013	Diabetes is associated with postural instability and gait difficulty in Parkinson disease.
4/2012	Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease.
8/2011	Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.
6/2011	Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography.
6/2010	Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease.
9/2006	Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.
6/2002	Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roger L Albin Research Topics

Disease

43	Parkinson Disease (Parkinson's Disease) 01/2022 - 07/2002
18	Dementia (Dementias) 08/2021 - 06/2002
15	Alzheimer Disease (Alzheimer's Disease) 08/2021 - 06/2002
11	Cognitive Dysfunction 08/2021 - 04/2010
10	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 05/2004
10	Huntington Disease (Huntington's Disease) 01/2021 - 03/2009
3	Parkinsonian Disorders (Parkinsonism) 01/2019 - 06/2015
3	Tourette Syndrome (Tourette's Syndrome) 01/2019 - 01/2006
3	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 08/2014 - 04/2002
2	Frontotemporal Dementia (Semantic Dementia) 08/2021 - 08/2012
2	Tremor (Tremors) 01/2021 - 05/2013
2	Hypokinesia (Bradykinesia) 01/2021 - 05/2013
2	REM Sleep Behavior Disorder 02/2015 - 04/2012
2	Leukoaraiosis 12/2014 - 05/2013
2	Movement Disorders (Movement Disorder) 04/2014 - 12/2012
2	Ataxia (Dyssynergia) 11/2003 - 08/2003
1	Tics (Tic) 01/2019
1	Late Onset Disorders 01/2018
1	Orthostatic Hypotension (Postural Hypotension) 11/2016
1	Proteostasis Deficiencies 10/2015
1	Neurobehavioral Manifestations 10/2013
1	Disease Progression 01/2013
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 10/2012
1	Corticobasal Degeneration 08/2012
1	Sleep Apnea Syndromes (Sleep Apnea) 01/2012
1	Leukoencephalopathies 08/2011
1	Gliosis 10/2010
1	Anosmia 06/2010
1	Hepatolenticular Degeneration (Wilson's Disease) 03/2009
1	Epilepsy (Aura) 09/2008
1	Androgen-Insensitivity Syndrome (Testicular Feminization) 01/2006
1	X-Linked Bulbo-Spinal Atrophy 01/2006

Drug/Important Bio-Agent (IBA)

24	Cholinergic Agents (Cholinergics)IBA 01/2022 - 01/2002
12	Proteins (Proteins, Gene)FDA Link 01/2019 - 11/2003
11	Amyloid (Amyloid Fibrils)IBA 01/2019 - 06/2011
10	polyglutamineIBA 01/2019 - 08/2003
10	dihydrotetrabenazineIBA 12/2014 - 04/2010
9	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2006
9	Dopamine (Intropin)FDA LinkGeneric 01/2022 - 01/2006
7	Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)IBA 05/2013 - 06/2002
4	Levodopa (L Dopa)FDA LinkGeneric 11/2016 - 05/2013
4	AcetylcholinesteraseIBA 10/2013 - 06/2010
3	Vesicular Acetylcholine Transport Proteins (Vesicular Acetylcholine Transporter)IBA 01/2022 - 07/2017
3	LigandsIBA 01/2022 - 11/2003
3	Serotonin (5 Hydroxytryptamine)IBA 01/2018 - 01/2012
3	PropionatesIBA 10/2013 - 06/2010
2	Pharmaceutical PreparationsIBA 01/2022 - 11/2016
2	fluoroethoxy-benzovesamicolIBA 01/2022 - 01/2021
2	Dopamine Agonists (Dopamine Agonist)IBA 01/2022 - 07/2002
2	LipidsIBA 09/2019 - 01/2019
2	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 01/2018 - 01/2013
2	UbiquitinIBA 10/2015 - 01/2013
2	RadiopharmaceuticalsIBA 02/2015 - 08/2014
2	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 03/2013 - 12/2012
2	Neurotransmitter Agents (Neurotransmitter)IBA 04/2012 - 08/2011
2	Glucose (Dextrose)FDA LinkGeneric 06/2011 - 04/2010
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 10/2010 - 03/2009
2	Huntingtin ProteinIBA 09/2010 - 03/2009
1	N- (4'- fluorobutyrophenone)- 4- (4- chlorophenyl)pyridinium (HPP(+))IBA 01/2022
1	2- tert- butyl- 4- chloro- 5- (6- (2- (2- fluoroethoxy)ethoxy)pyridin- 3- ylmethoxy)- 2H- pyridazin- 3- oneIBA 01/2022
1	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2022
1	Retinaldehyde (Retinal)IBA 08/2021
1	Cholinergic ReceptorsIBA 01/2021
1	Cholinergic Antagonists (Anticholinergics)IBA 01/2021
1	Carrier Proteins (Binding Protein)IBA 01/2019
1	SDMIBA 01/2019
1	ioflupaneIBA 01/2018
1	Proteasome Endopeptidase Complex (Proteasome)IBA 10/2015
1	MetalsIBA 02/2015
1	Alanine (L-Alanine)FDA Link 02/2015
1	Threonine (L-Threonine)FDA Link 02/2015
1	Apolipoproteins E (ApoE)IBA 11/2014
1	Lansoprazole (Prevacid)FDA LinkGeneric 08/2014
1	Deubiquitinating EnzymesIBA 01/2013
1	ubiquitin isopeptidaseIBA 01/2013
1	Ataxin-3IBA 01/2013
1	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 12/2012
1	CarbonIBA 12/2012
1	Adenosine Triphosphatases (ATPase)IBA 11/2012
1	Glutamic Acid (Glutamate)FDA Link 11/2012
1	P-2 (P 2)IBA 10/2012
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 08/2012
1	3- amino- 4- (2- dimethylaminomethylphenylsulfanyl)benzonitrileIBA 01/2012
1	N-Methylaspartate (NMDA)IBA 10/2010
1	Dopamine Receptors (Dopamine Receptor)IBA 10/2010
1	CalciumIBA 09/2010
1	CopperIBA 03/2009
1	tetrathiomolybdate (ammonium tetrathiomolybdate)IBA 03/2009
1	IonsIBA 03/2009
1	mortalinIBA 02/2008
1	ProteomeIBA 10/2007
1	Androgen Receptors (Androgen Receptor)IBA 01/2006
1	Glutamine (L-Glutamine)FDA Link 01/2006
1	Mutant Proteins (Protein, Mutant)IBA 01/2006
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 06/2005

Therapy/Procedure

18	Denervation 01/2021 - 07/2009
5	Therapeutics 01/2021 - 11/2003
2	Activities of Daily Living (ADL) 11/2016 - 09/2006
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2021
1	Institutionalization (Institutionalized Persons) 07/2014